We describe a follow-up of a study of behavior and emotional problems in a cohort of young people with Fragile X syndrome over 7 years. The study demonstrates that there is substantial persistence of the overall level of behavior and emotional problems. However, there are changes in certain types of
Double-blind, placebo-controlled study ofL-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome
β Scribed by Torrioli, M.G.; Vernacotola, S.; Mariotti, P.; Bianchi, E.; Calvani, M.; De Gaetano, A.; Chiurazzi, P.; Neri, G.
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 5 KB
- Volume
- 87
- Category
- Article
- ISSN
- 0148-7299
- DOI
- 10.1002/(sici)1096-8628(19991203)87:4<366::aid-ajmg18>3.0.co;2-f
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Fragile X syndrome (FRAXA) is the most common form of inherited mental retardation. The syndrome is caused by a CGG-expansion mutation in the gene FMR-1, located at Xq27.3. The morphologic anomalies in this syndrome can be subtle: elongated face, large ears, and macro-orchidism. More striking is the
Fragile X (FraX) syndrome is the most common cause of inherited mental retardation. The FraX gene (FMR1) has been cloned, and the mutation causing the disease is now known. We estimated the effect of FraX on dental development in 28 affected boys (aged 4.9-17.6 years) and three carrier girls (aged 5